SEC Form 4 · accession 0001610717-26-000274
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elaine V Jones
Director
Period of report
Jun 17, 2026
Accepted (ET)
Jun 22, 2026 · 4:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.96 | Jun 17, 2026 | A | 59,000 | A | — | Jun 16, 2036 | Common Stock | 59,000 | 59,000 | D |
Explanation of responses
- F1100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.